PolyNovo CEO Bruce Peatey talked with Proactive at the ASX Small and Mid-Cap Conference about its proprietary NovoSorb® polymer, the performance of the company, addressable market and what’s next for the company. PolyNovo (ASX: PNV) is a leading medical technology company transforming the management of complex wounds. Headquartered in Melbourne, Australia, it has international operations in the United States, United Kingdom, India, Hong Kong and Singapore and several other markets supported by distributor partners. The proprietary NovoSorb® polymer is addressing significant unmet needs in wound care, as evidenced by its clinical adoption and patient outcomes, and the Company is leveraging the technology platform to develop new products and markets. Achievements to date, including continued revenue growth, profitability, numerous clearances and registrations, as well as market leadership in several geographies, provide a strong foundation for continued growth. #PolynovoLimited #ProactiveInvestors #BrucePeatey #MedicalDevices #WoundCare